Elite Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024
July 01, 2024 at 04:59 pm
Share
Elite Pharmaceuticals, Inc. reported earnings results for the full year ended March 31, 2024. For the full year, the company reported revenue was USD 56.63 million compared to USD 34.16 million a year ago. Net income was USD 20.11 million compared to USD 3.56 million a year ago.
Basic earnings per share from continuing operations was USD 0.02. Diluted earnings per share from continuing operations was USD 0.02.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. The Company specializes in developing and manufacturing oral, controlled-release drug products. It owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Companyâs segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Companyâs products include Phentermine HCl 37.5mg tablets, Loxapine Succinate 5mg, 10mg, 25mg and 50gm capsules, Phentermine HCl 15mg and 30mg capsules, Naltrexone HCl 50mg tablets, Dantrolene Sodium Capsules 25mg, 50mg and 100mg, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and others.
ELITE PHARMACEUTICALS, INC. 
